RPG Life Sciences Ltd Stock Analysis

BSE: 532983 | NSE: RPGLIFE | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 06-Dec-2022 18:01
870.40 -22.35 (-2.50%)

DeciZen - Make an Informed Decision on RPG Life Sciences

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Semi Strong

RPG Life Sciences Price Chart

P/E Ratio (SA) :
Market Cap :
1,476.5 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is RPG Life Sciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a average quality company.

2. Is RPG Life Sciences Ltd undervalued or overvalued?

The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is RPG Life Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of RPG Life Sciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
RPG Life Sciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 6.7%6.3%1.6%8.2%13.6%8.3%6.8%17.9%20.2%21.9%-
Value Creation Index -0.5-0.6-0.9-0.4-0.0-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 222236242279294344330376389440483
YoY Gr. Rt. %-6.3%2.9%15.3%5.1%17.1%-4%13.8%3.6%13.1%-
YoY Gr. Rt. %-89.2%-93.3%2296.4%90%-37.1%-21.7%212.4%22.2%28.5%-
BVPS (₹)
Adj Net Profit 3.770.511.121.113.310.432.539.75160
Cash Flow from Ops. 12.3-5.6-232.87.314.745.850.258.364.8-
Debt/CF from Ops. 5.1-2.6-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.9%8.4%10.1%13.1%
Adj EPS 34%19.3%69.9%28.5%
BVPS 14.411.716.818.2
Share Price 26.2% 14.1% 45.2% 45.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity %
Op. Profit Mgn %
Net Profit Mgn % 1.730.
Debt to Equity
Working Cap Days 146154150137123126136115118105157
Cash Conv. Cycle 3136524849555548444098

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 22.60%

Sales growth is growing at healthy rate in last 3 years 10.06%

Net Profit is growing at healthy rate in last 3 years 69.94%

Sales growth is good in last 4 quarters at 14.55%

No data to display

Latest Financials - RPG Life Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) 36.5 5
TTM Sales (₹ Cr.) 483 121
BVPS (₹.) 168.1 0
Reserves (₹ Cr.) 265 -
P/BV 5.31 0.00
PE 24.47 179.22
From the Market
52 Week Low / High (₹) 451.80 / 1012.45
All Time Low / High (₹) 17.10 / 1012.45
Market Cap (₹ Cr.) 1,477
Equity (₹ Cr.) 13.2
Face Value (₹) 8
Industry PE 37.7

Management X-Ray of RPG Life Sciences :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of RPG Life Sciences

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


RPG Life Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of RPG Life Sciences on 06-Dec-2022 18:01 is : 870.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Dec-2022 18:01 the market cap of RPG Life Sciences stood at ₹ 1,476.5.
The latest PE ratio of RPG Life Sciences as of 06-Dec-2022 18:01 is 24.47.
The latest PB ratio of RPG Life Sciences as of 06-Dec-2022 18:01 is 5.31
The 52-week high of RPG Life Sciences is ₹ 1,012.5 and the 52-week low is ₹ 451.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of RPG Life Sciences is ₹ 483.1 ( Cr.) .

About RPG Life Sciences Ltd

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

  • Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
  • Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].

Company’s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

  • Dossiers/DMF Europe, Canada
  • Artificial Sweetner-UK
  • NSAID-Europe
  •  Formulations - Asia, Canada, Europe.


  • 8 processes patented granted,both in India and overseas
  • First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
  • One of the two manufacturers of Vitamin B12 in India
  • R&D approved  by Department of Science & Technology, Government of India.
  • Only manufacturer of Spironolactone, by the fermentation route, in India.
  • Marketing APIs and formulations catering to all key therapeutic areas across the world.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now